

RECEIVED

JAN 1 5 2003

Clone C35

TECH CENTER 1600/2900

DNA Coding Sequence

GCC GCG ATG AGC GGG GAG CCG GGG CAG ACG TCC GTA
GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT
GGG GTC CGC ATC GTG GTG GAG TAC TGT GAA CCC
TGC GGC TTC GAG GCG ACC TAC CTG GAG CTG GCC
AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG
ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT
GAG ATA GAG ATA AAT GGA CAG CTG GTG TTC TCC
AAG CTG GAG AAT GGG GGC TTT CCC TAT GAG AAA
GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT
GGA GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT
CCT CCC TGC GTC ATC CTG TGA

FIG.1A

Protein Sequence

MSGEPGQTSVAPPPEEVEPGSGVRIVVEYCEPCGFEATYLEL ASAVKEQYPGIEIESRLGGTGAFEIEINGQLVFSKLENGGFPY EKDLIEAIRRASNGETLEKITNSRPPCVIL*

FIG.1B



0.8 kb

GAPDH

C35 is Expressed at High Levels in Breast Tumors but Not Normal Tissues




FIG.2A


C35 isExpressed at High Levels inBreast Tumors but Not Normal Tissues

BRAIN
HEART
SKELETAL MUSCLE
COLON
ADULT THYMUS
SPLEEN
KIDNEY
LIVER
SMALL INTESTINE
PLACENTA
LUNG



FIG.2B

C35 isExpressed at High Levels in Breast Tumors but Not Normal Tissues T1 T2 T3 N



45 25 3 1

FIG.2C








FIG.3











		PECIFIC LYSIS R : TARGET
TARGET	10:1	2:1
BCA 34	68.4	54.8
BCA 39	36.6	23.4
B/C.N	0.2	0.3
B/C.N + vF5.8	47.5	34.6
B/C.N + vH2.16	67.8	56.2
B/C.N + VACCINIA VECTOR	0	0.2

FIG.5B

				-					
26	·	ATC				26	—	.	
55	I	GCC TTT CTG GGT TAC AAG GCT GGC ATG ACC CAC ATC				55	I	1	
54		ACC				54	-	+	
53	×	ATG				53	≥	!	
52		299				52	ပ		
51	⋖	SCT				51	⋖		
20	×	AAG	Ø			20	×	1	φ
49	>	TAC	FIG.6A			49	>-		FIG.6B
48	S	199	<u>=</u>			48	ပ	1	$\stackrel{\smile}{\vdash}$
47	_	CTG				46 47			
46	ட	111					Ŀ	-	
45	¥	၁၁				45	∢		
Amino Acid Position	Sequence	Nucleotide			H2.16	Amino Acid Position	Sequence		



		PECIFIC LYSIS R : TARGET
TARGET	<u>10:1</u>	2:1
BCA 34	62.4	32.1
BCA 39	49.7	23.6
B/C.N	3.3	0.2
B/C.N + L3 PEPTIDE 48-56 (I54)	46.0	16.1
B/C.N + L3 PEPTIDE 48-56 (T54)	2.0	0
B/C.N + L3 PEPTIDE 45-54 (154)	0	0

FIG.7A







FIG.7B



PUBLISHED L3 (1276 bp)

2	00 	555 	903	1192
200	355	348	. 2	89 84

168-171=GACC



168-171=GATC

FIG.8A







FIG.8B



PLANT FOR

Appl. No. 09/824 787; Filed: April 4, 2001 Dkt. No. 1821.0040001; Group Art Unit: 1642 Inventors: ZAUDERER et al.; Tel: 202/371-2600 Title: Gene Differentially Expressed in Breast and Bladder Cancer, and Encoded Polypeptides





PERCENT SPECIFIC LYSIS IMMUNOGEN

	¥	vH2.16	v7.5/tk	/ŧ
TARGET	40:1	10:1	40:1	10:1
BCA 34	33.6	12.9	5.7	4.0
BCA 39	22.1	0.6	5.3	3.1
B/C.N + L3 48-56 (154)	48.2	20.2	3.9	1.5
B/C.N + L3 48-56 (T54)	6.4	1.4	1.8	2.9
B/c.N	7.1	5.7	6.1	2.8
YAC	1.2	2.5	0	6 .

FIG.9A









FIG.9B









GTA GCG CCC CCT CCC GAG GAG GTC GAG CCG GGC AGT GGG GTC CGC Р Р Ε Ε E Р G ٧ ATC GTG GTG GAG TAC TGT GAA CCC TGC GGC TTC GAG GCG ACC TAC CTG GAG CTG GCC AGT GCT GTG AAG GAG CAG TAT CCG GGC ATC GAG S Κ E Y ٧ 0 ATC GAG TCG CGC CTC GGG GGC ACA GGT GCC TTT GAG ATA GAG ATA S G G AAT GGA CAG CTG GTG TTC TCC AAG CTG GAG AAT GGG GGC TTT CCC Ν G F S K E G G F Ρ TAT GAG AAA GAT CTC ATT GAG GCC ATC CGA AGA GCC AGT AAT GGA

gcccgagcggagccgccqcq ATG AGC GGG GAG CCG GGG CAG ACG TCC

CTG TGA ctgcacaggactctgggttcctgctctgttctggggtccaaaccttggtct

GAA ACC CTA GAA AAG ATC ACC AAC AGC CGT CCT CCC TGC GTC ATC

R

R

I

S

R

P

F

Ī


Ε

K

FIG. 10A







Title: Gene Differentially Expressed in Breast and Bladder

Cancer, and Encoded Polypeptides



Breast epithelial cell lines

21NT TUMOR H16N2 (normal) T47D TUMOR **SKBK3 LOMOK** BL414 LOWOR MDA231 TUMOR **MCF7 TUMOR** BT20 TUMOR


B-actin


18 70 14

TUMOR Primary 21PT TUMOR Primary 21NT

3 Week Thymus

TUMOR Metastatic 21MT2 TUMOR Metastatic 21MT1 NORMAL Breast H16N2





Sheet 21 of 28

Appl. No. 09/824,787; Filed: April 4, 2001
Dkt. No. 1821,0040001; Group Art Unit: 1642
Inventors: ZAUDERER et al.; Tel: 202/371-2600
Title: Gene Differentially Expressed in Breast and Bladder Cancer, and Encoded Polypeptides

11 1N 2T 2N 2N 3N 4T 4N

C35 →



95 1 211 1


B-actin




FIG.12

JAN 14 2003

Appl. No. 09/824,787; Filed: April 4, 2001
Dkt. No. 1821,0040001; Group Art Unit: 1642
Inventors: ZAUDERER et al.; Tel: 202/371-2600
Title: Gene Differentially Expressed in Breast and Bladder
Cancer, and Encoded Polypeptides





80-

COUNTS \$

JAN 1 4 2003



21NT BREAST TUMOR




FIG.14A

HI6N2 NORMAL BREAST




FIG.14B



LYTIC ACTIVITY OF C35-SPECIFIC T CELL LINE 4




FIG.15A

LYTIC ACTIVITY OF C35-SPECIFIC T CELL CLONE 10G3





FIG.15B






FIG.16A






FIG. 16B



TOLERANCE TO ALLOANTIGENS INDUCED IN PRESENCE OF ANTIGENS AND ANTI-CD40 LIGAND ANTIBODY




FIG.17A

